Biocon expects to earn Rs 100 crore from Psoriasis over the next four years

The Company plans to launch the drug under the Alzumab brand.


New Delhi, January 25, 2013: The Indian biotechnology firm, Biocon, today announced that the company will launch a skin disease drug under the brand Alzumab in India in 2013 and is eying Rs 100 crore in sales over the next four years from the product.


The company said that it will launch the product during the second quarter of the current year. The company has invested close to Rs 100 crore on developing the product. It is to be mentioned here that the company received approval from drug controller (DCGI) to market 'Itolizumab', used in the treatment of psoriasis earlier this year. It would be launched under the brand name, Alzumab.


The global Psoriasis market size is estimated to cross US$ 8 billion by 2016. The product from Biocon will be manufactured and formulated as an infusion drug at Biocon's biopharma manufacturing facility at Biocon Park, Bengaluru.


* Indicates mandatory field.
Please wait while comments are being sent...